1. [The role of biologics into the management of psoriasis: a consensus paper by the Psoriasis Study Group, Arbeitsgemeinschaft Dermatologische Forschung].
- Author
-
Wolf-Henning B, Friedrich M, Mrowietz U, Reich K, Rosenbach T, Sticherling M, and Thaçi D
- Subjects
- Arthritis, Psoriatic diagnosis, Arthritis, Psoriatic drug therapy, Biological Products adverse effects, Biological Products economics, Drug Approval, Drug Costs statistics & numerical data, Germany, Humans, Immunosuppressive Agents adverse effects, Immunosuppressive Agents economics, Psoriasis economics, Psoriasis immunology, Treatment Outcome, United States, United States Food and Drug Administration, Biological Products therapeutic use, Immunosuppressive Agents therapeutic use, Psoriasis drug therapy
- Abstract
About 20% of all psoriasis patients require photo- and/or systemic therapy because of the severity of their disease. Side effects, contraindications, insufficient clinical responses, and lack of long-term efficacy underline the need for novel and improved anti-psoriatic therapies. In recent years, the technology has been established to generate therapeutic molecules from living cells capable of inhibiting disease-relevant mediators or cell-cell interactions. Several of these so-called biologics interfering with key steps in the immunopathogenesis of psoriasis have the potential to meet this need with regard to treating moderate to severe psoriasis. Here, the Psoriasis Study Group of the Arbeitsgemeinschaft Dermatologische Forschung (ADF) analyses the established anti-psoriatic treatment modalities. With the shortcomings of these options in mind, biologics with an immediate relevance for clinical application in the treatment of psoriasis are discussed. The focus is on their potential medical advantages along with safety aspects. Moreover, legal and economical aspects with an impact on the use of biologics are addressed.
- Published
- 2003
- Full Text
- View/download PDF